Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting

Sponsor
Novartis Pharmaceuticals
Study ID
NCT01318941
Status
Completed

Conditions

  • Diabetic Macular Edema
  • Retinal Vein Occlusion
  • Wet Age Related Macular Degeneration
  • Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in the local product label.

Key Dates

First listed
Mar 21, 2011
Start date
Mar 31, 2011
Status verified
May 2016
Primary completion
Apr 30, 2016
Completion
Apr 30, 2016

Study Design

Enrollment
30,490 participants (actual)

Arms

  • Arm: Ranibizumab

Primary Outcome Measure

Mean Visual Acuity (VA) and mean change in VA [ Time Frame: 3,6, and 12 months from the baseline visit, and annually thereafter ]

Related Studies